In this interview from AAO 2014, Dr. Usha Chakravarthy talks about the long-term systemic safety profile of anti-VEGF therapy as gleaned from the landmark clinical trials CATT and IVAN. One of the unanswered questions is whether or not there’s a difference in the safety profile among the drugs, and how a long-term regimen may impact that profile. Dr. Chakravarthy offers her approach for treating patients with a history of stroke, whom she would treat confidently with ranibizumab. Patients with diabetes she would also treat with ranibizumab, although she has reservations about long-term therapy in this population due to additional potential systemic risk factors and comorbidities.